AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04108325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
Study NCT01691248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fidaxomicin
Description: Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Study NCT01691248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Study NCT02194309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low
Study NCT02194309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high
Study NCT02194309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Study NCT00455052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1001
Description: XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
Study NCT01003132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
Study NCT01586247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis
Study NCT01586247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 8g/day maltodextrin
Study NCT01586247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 8g/day galacto-oligosaccharide
Study NCT01586247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 10\^9 CFU/day B.lactis
Study NCT00927147 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT
Description: Boronophenylalanine infusion followed by neutron irradiation
Study NCT00927147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
Study NCT05132309 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: enzyme replacement therapy
Description: Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
Study NCT03746353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early ileostomy closure
Description: Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
Study NCT03746353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early ileostomy closure
Description: Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
Study NCT01890915 — intervention group
Intervention type: OTHER
Intervention: Heat Exposure
Description: Heat exposure of 95 degrees F for up to 2 hours.
Study NCT01759290 — intervention group
Intervention type: DEVICE
Intervention: Absorb Bioresorbable Vascular Scaffold
Description: Subjects receiving the Absorb Bioresorbable Vascular Scaffold
Study NCT03810430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health promotion
Description: health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
Study NCT00966225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIP-01
Description: comparison of different dosages of natural health product
Study NCT03495661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
Study NCT00674180 — intervention group
Intervention type: BEHAVIORAL
Intervention: Workbook
Description: The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
Study NCT00674180 — intervention group
Intervention type: BEHAVIORAL
Intervention: Computer Intervention
Description: The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
Study NCT00674180 — intervention group
Intervention type: BEHAVIORAL
Intervention: Staff Consultation
Description: The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
Study NCT03150251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal - oats
Description: Consumption of one cereal in the beginning of each visit
Study NCT03150251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cereal - cream of rice
Description: Consumption of one cereal in the beginning of each visit
Study NCT00408902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally, 500 mg bid daily
Study NCT00408902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02053532 — intervention group
Intervention type: PROCEDURE
Intervention: Positron emission tomography/magnetic resonance imaging
Description: Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
Study NCT00682305 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplantation
Description: conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT
Study NCT05629949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1701
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Study NCT05629949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Study NCT04290936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemlidy® (Tenofovir Alafenamide; TAF)
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Study NCT05629949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
Study NCT05629949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
Study NCT03934073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEXTRAIN
Description: 12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
Study NCT03934073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONNELLE
Description: 12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
Study NCT03934073 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CONTROLE
Description: Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
Study NCT02946385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
Study NCT02946385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
Study NCT02946385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal B Recombinant vaccine
Description: Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
Study NCT02946385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal B Recombinant vaccine
Description: Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
Study NCT04332978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Study NCT04332978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Study NCT04290936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
Study NCT03356782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sarcoma-specific CAR-T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
Study NCT00625248 — intervention group
Intervention type: DRUG
Intervention: Antithrombotics
Description: With or without or discontinuted use of Antithrombotics
Study NCT00735020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Influenza Vaccine
Description: 1 dose of Adjuvanted Influenza Vaccine
Study NCT00735020 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: 1 dose of Influenza Vaccine
Study NCT03361280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Beta blockers are administered as described in arms.
Study NCT03624348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meditation
Description: 10 minute per day, 8 week digital meditation
Study NCT01352117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: 600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
Study NCT01352117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate
Description: 600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
Study NCT01352117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
Study NCT01352117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
Study NCT00633477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
Study NCT00633477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
Study NCT04532268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized CD19 CAR-T cells
Description: Each subject receive humanized CD19 CAR T-cells by intravenous infusion
Study NCT03121313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Study NCT03897426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet - Remote Coaching using a Mobile App
Description: Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
Study NCT04002960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00036
Description: Noninvasive regional oximeter
Study NCT01288573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 160 μg/kg subcutaneous (SC) injection
Study NCT01288573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 240 μg/kg subcutaneous (SC) injection
Study NCT01288573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 320 μg/kg subcutaneous (SC) injection
Study NCT00708292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study NCT00708292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT00708292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01649895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
Study NCT01649895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills as adjunct to internet-based cognitive-behaviour therapy
Study NCT00179621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Description: Lenalidomide 5 mg daily 28/28 days
Study NCT00179621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg
Description: Lenalidomide 10 mg daily 21/28 days
Study NCT00179621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matching to active study drug arms
Study NCT01777308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal conjugate vaccine GSK134612
Description: Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
Study NCT03567564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal muscles ultrasound
Description: Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
Study NCT03363737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model
Description: Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
Study NCT03363737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transtheoretical Model
Description: Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
Study NCT02718079 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Management of cerebral edema/intracranial hypertension:
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of cerebral edema/intracranial hypertension:
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfer to Intensive Care Unit
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer to Intensive Care Unit
Study NCT02718079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Antibiotics
Study NCT00417261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATF936
Study NCT00417261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATF936
Study NCT02718079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Antibiotics
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation of trachea
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intubation of trachea
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Replacement
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume Replacement
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressor Support
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressor Support
Study NCT02718079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-L-cysteine
Study NCT02718079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Correction of metabolic parameters
Study NCT02718079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correction of metabolic parameters
Study NCT02718079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Correction of nutrition
Study NCT02718079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Correction of nutrition
Study NCT03896139 — intervention group
Intervention type: DRUG
Intervention: Kinase inhibitor
Description: Patients treated with kinase inhibitors for cancer or other conditions